Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $25

Benzinga · 1d ago
Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $35 to $25.